Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China NT Pharma Group CoHKSE:01011 -6.67%1 Quick Ratio is 0.02 as of Dec. 2025, which is 91% below its 10-year median of 0.22. GuruFocus rates HKSE:01011 with a GF Score™ of 1/100. The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, China NT Pharma Group Co ranks worse than 98.39% on this metric.
China NT Pharma Group Co (HKSE:01011) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
China NT Pharma Group Co Quick Ratio Related Terms
China NT Pharma Group Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
China NT Pharma Group Co's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) has a Quick Ratio of 0.02 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China NT Pharma Group Co and its competitors. This is 91% below median its historical median of 0.22. Over the past decade, China NT Pharma Group Co's Quick Ratio has ranged from 0.02 to 0.85. According to the industry distribution chart, China NT Pharma Group Co ranks #979 out of 995 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is China NT Pharma Group Co's Quick Ratio too high?
China NT Pharma Group Co's current Quick Ratio of 0.02 is 91% below median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.85. The Drug Manufacturers industry median Quick Ratio is 1.39. China NT Pharma Group Co's value of 0.02 is 98.6% below this industry median. Based on the distribution chart, China NT Pharma Group Co ranks #979 out of 995 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China NT Pharma Group Co ranks #979 out of 995 companies for Quick Ratio. This places China NT Pharma Group Co in the lower half of its industry. The industry median Quick Ratio is 1.39. China NT Pharma Group Co's value of 0.02 is 98.6% below this benchmark. Historically, China NT Pharma Group Co's own Quick Ratio has ranged from 0.02 to 0.85 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 1.39, China NT Pharma Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.39, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China NT Pharma Group Co's current Quick Ratio of 0.02 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on China NT Pharma Group Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China NT Pharma Group Co's current Quick Ratio is 0.02, which is 91% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current Quick Ratio of 0.02. The current Quick Ratio is 0.02, which is 91% below median its 10-year median of 0.22 and 98.6% below the Drug Manufacturers industry median of 1.39. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current Quick Ratio is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score
Get the complete analysis for HKSE:01011
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01011 has been successfully added to your 
